Publications
Detailed Information
Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Hye-Suk | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Park, Jin Hyun | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Park, So Yeon | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2012-05-24T07:21:46Z | - |
dc.date.available | 2012-05-24T07:21:46Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2009-10 | - |
dc.identifier.citation | Journal of Korean Medical Science, Vol.24 No.5, pp.910-917 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.other | 119423 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76439 | - |
dc.description.abstract | We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as first-line chemotherapy in women with HER2-overexpressing metastatic breast cancer (MBC), and we investigated the prognostic factors including magnitude of HER2/neu amplification in this population. We analyzed 54 patients with HER2-overexpressing MBC that were treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy from February 2004 to December 2006. At a median follow-up of 28 months, median time to progression (TTP) was 16.6 months (95% Cl, 9.4 to 23.7 months) and median overall survival was 25.6 months (95% Cl, 21.8 to 27.3 months). Therapy was generally well tolerated, although three patients (5.5%) experienced reversible, symptomatic heart failure. Of the 27 patients evaluable for the HER2 FISH, patients with a HER2/CEP17 ratio of <= 4.0 had significantly shorter TTP than those with a HER2/CEP17 ratio of >4.0 (10.8 vs. 23.2 months, P=0.034). A HER2/CEP17 ratio of >4.0 was identified as significant predictive factor of TTP by multivariate analysis (P=0.032). The combination of weekly paclitaxel plus trastuzumab as first-line chemotherapy is an effective regimen in patients with HER2-FISH-positive MBC. Furthermore, the magnitude of HER2 amplification is an independent predictive factor of TTP. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | 대한의학회 | - |
dc.title | Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.3346/jkms.2009.24.5.910 | - |
dc.citation.journaltitle | Journal of Korean Medical Science | - |
dc.description.citedreference | Seidman AD, 2008, J CLIN ONCOL, V26, P1642, DOI 10.1200/JCO.2007.11.6699 | - |
dc.description.citedreference | Azambuja E, 2008, ANN ONCOL, V19, P223, DOI 10.1093/annonc/mdm352 | - |
dc.description.citedreference | Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475 | - |
dc.description.citedreference | Gasparini G, 2007, BREAST CANCER RES TR, V101, P355, DOI 10.1007/s10549-006-9306-9 | - |
dc.description.citedreference | Giuliani R, 2007, EUR J CANCER, V43, P725, DOI 10.1016/j.ejca.2006.11.019 | - |
dc.description.citedreference | Stemmler HJ, 2007, ANTI-CANCER DRUG, V18, P23 | - |
dc.description.citedreference | Gabos Z, 2006, J CLIN ONCOL, V24, P5658 | - |
dc.description.citedreference | Frasci G, 2006, BRIT J CANCER, V95, P1005, DOI 10.1038/sj.bjc.6603395 | - |
dc.description.citedreference | Dal Lago L, 2006, MOL CANCER THER, V5, P2572, DOI 10.1158/1535-7163.MCT-06-0129 | - |
dc.description.citedreference | Stemmler HJ, 2006, BREAST, V15, P219, DOI 10.1016/j.breast.2005.04.017 | - |
dc.description.citedreference | Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091 | - |
dc.description.citedreference | Eniu A, 2005, ONCOLOGIST, V10, P665 | - |
dc.description.citedreference | Emens LA, 2004, ONCOLOGY-NY, V18, P1117 | - |
dc.description.citedreference | Pegram MD, 2004, J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131 | - |
dc.description.citedreference | Gori S, 2004, BRIT J CANCER, V90, P36, DOI 10.1038/sj.bjc.6601485 | - |
dc.description.citedreference | Loesch D, 2002, J CLIN ONCOL, V20, P3857, DOI 10.1200/JCO.2002.08.129 | - |
dc.description.citedreference | Perez EA, 2001, J CLIN ONCOL, V19, P4216 | - |
dc.description.citedreference | Seidman AD, 2001, J CLIN ONCOL, V19, P2587 | - |
dc.description.citedreference | Slamon DJ, 2001, NEW ENGL J MED, V344, P783 | - |
dc.description.citedreference | Lebeau A, 2001, J CLIN ONCOL, V19, P354 | - |
dc.description.citedreference | Fountzilas G, 2001, ANN ONCOL, V12, P1545 | - |
dc.description.citedreference | Pauletti G, 2000, J CLIN ONCOL, V18, P3651 | - |
dc.description.citedreference | Therasse P, 2000, J NATL CANCER I, V92, P205 | - |
dc.description.citedreference | Seidman AD, 1998, J CLIN ONCOL, V16, P3353 | - |
dc.description.citedreference | Andrulis IL, 1998, J CLIN ONCOL, V16, P1340 | - |
dc.description.tc | 4 | - |
dc.identifier.wosid | 000270520300023 | - |
dc.identifier.scopusid | 2-s2.0-75349110547 | - |
dc.citation.endpage | 917 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 910 | - |
dc.citation.volume | 24 | - |
dc.identifier.sci | 000270520300023 | - |
dc.identifier.kciid | ART001384449 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Park, So Yeon | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | HER-2/NEU GENE AMPLIFICATION | - |
dc.subject.keywordPlus | IN-SITU HYBRIDIZATION | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | BRAIN METASTASES | - |
dc.subject.keywordPlus | IMMUNOHISTOCHEMISTRY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordAuthor | Breast Neoplasms | - |
dc.subject.keywordAuthor | In Situ Hybridization, Fluorescence | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Trastuzumab | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.